Study Groups

Development of statistical methods to infer the relationship between the percentage of resistant infections, parasite clearance half-life and the proportion of treated individuals still positive on days one, two and three of treatment

A pooled analysis assessing the effect of mg/kg dosing strategies on the risk of treatment failure in patients treated with the currently recommended dose of artesunate-mefloquine (AS-MQ).

Research groups with relevant data have been contacted with data collection and curation still ongoing. Analysis will start in late 2016 and drafting publication in expected in 2018.

The Piperaquine Safety Study Group’s aim is to establish the evidence-base and safety profile to inform decision-making on the use and optimal dosing of dihydroartemisinin-piperaquine in all key target populations.

The study group call for contributors opened in June 2016 with a first scoping meeting held in July. Data collection is planned to close by end of 2016, with analysis due in 2018-2019.

The Subpatent Malaria and Pregnancy Outcome Study Group aims to explore the relationship between subpatent Plasmodium falciparum malaria infection and pregnancy outcome

An analysis of pooled individual patient data to determine the effect of antiretroviral (ARV) drug-drug interactions and HIV disease on lumefantrine pharmacokinetics (and pharmacodynamics).

This study group has just opened for data collection. If you have any data you would like to share, or if you would like to participate in the project, please contact pharmacology@wwarn.org.

Assessing the efficacy of a range of antimalarials used for the treatment of P. falciparum malaria in all trimesters of pregnancy in Africa and Asia

The MiP Treatment Efficacy Study Group was formed in July 2016, with a call to interested researchers with relevant data sets.

Baseline information on parasitological response to ACTs in Asia

A pooled analysis to assess the baseline early parasitological response after artemisinin combination therapy (ACT) treatment in Asia. The analysis compiles the day 3 parasite positivity rates (PPR) in patients with uncomplicated Plasmodium falciparum malaria enrolled in ACT clinical efficacy trials conducted in Asia.

Data gathering and curation has started. Data meeting the inclusion criteria has already been collected and standardised from over 12,000 patients. Data analysis will start April 2015 with a manuscript schedules for submission and publication by December 2015.